ciclesonide - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.98 [0.06, 15.76]< 10%2 studies (2/-)50.5 %some concernnot evaluable moderatecrucial-
deaths 0.98 [0.06, 15.76]< 10%2 studies (2/-)50.5 %some concernnot evaluable moderatecrucial-
hospitalization or death 0.39 [0.09, 1.67]< 10%1 study (1/-)89.7 %lownot evaluable highcrucial-
clinical improvement (14-day) 1.19 [0.78, 1.81]> 10%1 study (1/-)79.1 %lownot evaluable highimportant-
clinical improvement (28-day) 1.28 [0.84, 1.96]> 10%1 study (1/-)87.2 %lownot evaluable highimportant-
clinical improvement (7-day) 0.92 [0.51, 1.66]> 10%1 study (1/-)39.1 %lownot evaluable highimportant-
hospitalization 1.92 [0.47, 7.89]< 10%1 study (1/-)18.4 %some concernnot evaluable moderateimportant-
recovery 1.25 [0.71, 2.22]> 10%1 study (1/-)78.2 %some concernnot evaluable moderatenon important-

safety endpoints 00

adverse events 0.82 [0.43, 1.57]< 10%1 study (1/-)72.7 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.